Recombinant activated factor VII safety and efficacy in the treatment of cranial haemorrhage in patients with congenital haemophilia with inhibitors: an analysis of the Hemophilia and Thrombosis Research Society Registry (2004–2008)
Authors:
- 21 June 2010
- journal article
- research article
- Published by Wiley in Haemophilia
- Vol. 16 (4) , 625-631
Abstract
Summary. Cranial haemorrhage (CH) is a potentially serious complication in patients with severe congenital haemophilia with inhibitors (CHwI). Treatment includes bypassing agents, such as recombinant activated factor VII (rFVIIa). To examine the US experience in treating CH with rFVIIa, a retrospective review of the Hemophilia and Thrombosis Research Society 2004–2008 database was conducted. Among 29 patients with CHwI, 56 of the reported haemorrhages met the study criteria. Of these, 75% were traumatic and 80% were extracranial (ECH). The majority (8/11, 73%) of intracranial haemorrhages (ICHs) developed spontaneously. Conversely, most ECHs (39/45, 87%) followed trauma. ICHs were treated with a median/mean of 23/58 rFVIIa infusions over a median/mean of 7/9 days while ECHs were treated with a median/mean of 1/3 infusions (P = 0.011) over a median/mean of 1/1 day. The median/mean initial rFVIIa doses for all CHs were 106/137 μg kg−1, and were similar for ICHs and ECHs. All ECHs were effectively controlled with rFVIIa; 44/45 bleeds were controlled within 24 h, one bleed was successfully treated perioperatively, and 27 ECHs required only a single dose. Nine out of 11 ICHs were effectively treated with rFVIIa; six ICHs were controlled within 24 h, one within 72 h and in two cases haemostasis was achieved during the perioperative period. No serious treatment‐associated adverse events were reported. One patient died as a result of ICH despite the reported control of bleeding. In conclusion, standard dosing of rFVIIa was found to be safe and effective in treating CH with an efficacy rate of 100% for ECH and 82% for ICH.Keywords
This publication has 29 references indexed in Scilit:
- Intracranial haemorrhage in haemophilia A and BBritish Journal of Haematology, 2007
- Intracranial bleeding in haemophilia beyond the neonatal period – the role of CT imaging in suspected intracranial bleedingHaemophilia, 2007
- Inhibitor development in haemophilia B: an orphan disease in need of attentionBritish Journal of Haematology, 2007
- Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for deathHaemophilia, 2005
- Inhibitors to Factor VIII—Epidemiology and Treatment2005
- The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977–99Journal of Thrombosis and Haemostasis, 2004
- Changes in the occurrence of and risk factors for hemophilia‐associated intracranial hemorrhageAmerican Journal of Hematology, 2001
- Prevalence and incidence of intracranial haemorrhage in a population of children with haemophiliaHaemophilia, 1999
- Recombinant factor VIIa for intracranial haemorrhage in a Jehovahʼs Witness with severe haemophilia A and factor VIII inhibitorsBlood Coagulation & Fibrinolysis, 1993
- Intracranial Hemorrhage in Patients with HemophiliaNeurosurgery, 1986